Cerus (NASDAQ:CERS) Insider Sells 30,000 Shares of Stock

by · The Cerbat Gem

Cerus Corporation (NASDAQ:CERS – Get Free Report) insider Chrystal Jensen sold 30,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $2.98, for a total value of $89,400.00. Following the sale, the insider directly owned 936,657 shares in the company, valued at approximately $2,791,237.86. This trade represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Chrystal Jensen also recently made the following trade(s):

  • On Tuesday, June 30th, Chrystal Jensen sold 24,329 shares of Cerus stock. The stock was sold at an average price of $2.94, for a total value of $71,527.26.

Cerus Price Performance

CERS stock traded down $0.01 during midday trading on Monday, reaching $2.97. The company had a trading volume of 2,967,491 shares, compared to its average volume of 3,095,037. The company has a market capitalization of $598.51 million, a price-to-earnings ratio of -99.00 and a beta of 1.81. The stock has a 50 day moving average price of $2.81 and a 200-day moving average price of $2.43. Cerus Corporation has a 1-year low of $1.15 and a 1-year high of $3.47. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.83 and a quick ratio of 1.07.

Cerus (NASDAQ:CERS – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 3.06% and a negative return on equity of 10.19%. The firm had revenue of $63.30 million for the quarter, compared to the consensus estimate of $62.90 million. Equities research analysts expect that Cerus Corporation will post -0.04 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors raised its stake in Cerus by 15.3% during the 4th quarter. Captrust Financial Advisors now owns 37,051 shares of the biotechnology company’s stock worth $76,000 after buying an additional 4,916 shares during the period. Bank of New York Mellon Corp grew its stake in Cerus by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 507,455 shares of the biotechnology company’s stock valued at $924,000 after acquiring an additional 5,365 shares during the period. Engineers Gate Manager LP raised its position in shares of Cerus by 4.7% during the fourth quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 6,415 shares during the period. Stephens Inc. AR lifted its holdings in shares of Cerus by 6.9% in the 1st quarter. Stephens Inc. AR now owns 103,192 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 6,651 shares in the last quarter. Finally, Intech Investment Management LLC grew its position in Cerus by 8.6% in the 3rd quarter. Intech Investment Management LLC now owns 93,343 shares of the biotechnology company’s stock valued at $148,000 after purchasing an additional 7,355 shares during the period. Institutional investors and hedge funds own 78.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CERS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Wall Street Zen cut Cerus from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Cerus presently has an average rating of “Hold” and an average price target of $4.00.

Read Our Latest Research Report on CERS

About Cerus

(Get Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.

See Also